Liv Hospital (Ulus) Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04898088
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Liv Hospital (Ulus)

Active Ingredients

Drugs in Phase 2 Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Drugs in Other Trials (1)

allogeneic mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Multiple Organ Failure (Phase 2)

Pneumonia (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2